Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review

Weight Changes With Integrase Strand Transfer Inhibitor Therapy in the Management of HIV Infection: A Systematic Review

(2022) E.Kelly Hester et al.   ANNALS OF PHARMACOTHERAPY

HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance

(2021) Nokuzola Mbhele et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study

(2021) Debbie Hagins et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety

(2020) Kimberly K. Scarsi et al.   DRUGS

Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study

(2020) Edwin Hayes et al.   Open Forum Infectious Diseases

Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice

(2020) Gianmaria Baldin et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced Patients

(2020) Jason J Schafer et al.   Open Forum Infectious Diseases

Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era

(2020) Stephanie A. Ruderman et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?

(2019) Kristina M. Brooks et al.   PHARMACOTHERAPY

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2019) David A Wohl et al.   Lancet HIV

Bictegravir

(2018) Vincenzo Spagnuolo et al.   Current Opinion in HIV and AIDS

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

(2018) Jean-Michel Molina et al.   Lancet HIV

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

(2018) Eric S Daar et al.   Lancet HIV

PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation

(2018) Andrea C. Tricco et al.   ANNALS OF INTERNAL MEDICINE

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2018) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection

(2018) Emma D. Deeks   DRUGS

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2017) Paul E Sax et al.   LANCET

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials

(2011) David Moher et al.   International Journal of Surgery